Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ossianix Cracks Open The Blood-Brain Barrier

Executive Summary

By using the binding region of shark antibodies as a carrier to cross the blood-brain barrier, Ossianix reckons it has made significant progress against an issue that has held back the development of CNS-active neurological therapies.

You may also be interested in...



AdAlta CEO On Shark Antibody Technology

AdAlta CEO Sam Cobb discusses development of the company's novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.

Lundbeck funds propel Ossianix towards Series A in 2013

A strategic investment from CNS specialist H. Lundbeck A/S will allow Ossianix to undertake preclinical proof-of-concept studies that, in turn, could permit the Philadelphia-based start-up to raise further money in a Series A round sometime in 2013, according to CEO Frank Walsh.

Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab

With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel